Author: Chu, Helen Y.; Renaud, Christian; Ficken, Elle; Thomson, Blythe; Kuypers, Jane; Englund, Janet A.
Title: Respiratory Tract Infections Due to Human Metapneumovirus in Immunocompromised Children Document date: 2014_10_21
ID: ujvbm6ae_2
Snippet: The treatment of hMPV is mainly supportive. Animal data support the use of bronchodilators and corticosteroids, but no controlled trials have been done to assess their efficacy in human populations [10] . Ribavirin is a nucleoside analogue shown in in-vitro studies to have activity against hMPV [11] . Ribavirin is approved for use in treatment of respiratory syncytial virus (RSV), and is often used in combination with intravenous immunoglobulin (.....
Document: The treatment of hMPV is mainly supportive. Animal data support the use of bronchodilators and corticosteroids, but no controlled trials have been done to assess their efficacy in human populations [10] . Ribavirin is a nucleoside analogue shown in in-vitro studies to have activity against hMPV [11] . Ribavirin is approved for use in treatment of respiratory syncytial virus (RSV), and is often used in combination with intravenous immunoglobulin (IVIG) in severely immunocompromised individuals. Few prior descriptions of the clinical management and treatment of hMPV respiratory tract infections in a pediatric immunocompromised population, including children with leukemia and solid organ transplant recipients, are available. We describe hMPV respiratory tract infections in 55 pediatric immunocompromised patients at Seattle Children's Hospital, reporting on their clinical presentation, management, and outcomes.
Search related documents:
Co phrase search for related documents- clinical management and efficacy assess: 1, 2, 3, 4, 5, 6
- clinical management and human population: 1, 2, 3, 4
- clinical management and intravenous immunoglobulin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical management and IVIG intravenous immunoglobulin: 1, 2, 3, 4, 5, 6, 7, 8
- clinical management and IVIG intravenous immunoglobulin combination: 1
- clinical management and nucleoside analogue: 1
- clinical management and outcome management: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical management and outcome management clinical presentation: 1, 2, 3, 4, 5, 6
- clinical presentation and control trial: 1, 2, 3
- clinical presentation and efficacy assess: 1, 2, 3, 4
- clinical presentation and hmpv describe: 1
- clinical presentation and hmpv treatment: 1, 2
- clinical presentation and human population: 1, 2
- clinical presentation and intravenous immunoglobulin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- clinical presentation and IVIG intravenous immunoglobulin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- clinical presentation and IVIG intravenous immunoglobulin combination: 1
- clinical presentation and outcome management: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- clinical presentation and outcome management clinical presentation: 1, 2, 3, 4, 5, 6
- control trial and efficacy assess: 1, 2, 3, 4, 5, 6, 7
Co phrase search for related documents, hyperlinks ordered by date